tiprankstipranks
Ligand Pharma (LGND)
NASDAQ:LGND
US Market

Ligand Pharma (LGND) Income Statement

Compare
802 Followers

Ligand Pharma Income Statement

Last quarter (Q3 2024), Ligand Pharma's total revenue was $51.81M, an increase of 57.64% from the same quarter last year. In Q3, Ligand Pharma's net income was $-7.17M. See Ligand Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 131.31M$ 196.25M$ 277.13M$ 186.42M$ 120.28M
Gross Profit
$ 96.27M$ 143.42M$ 214.96M$ 156.00M$ 108.94M
Operating Expenses
$ 84.32M$ 140.38M$ 136.06M$ 147.27M$ 114.66M
Depreciation and Amortization
$ 37.41M$ 43.39M$ 41.34M$ 27.97M$ 43.73M
EBITDA
$ 101.73M$ 54.41M$ 133.16M$ 69.05M$ 38.01M
Operating Income
$ 11.94M$ -25.50M$ 78.89M$ 8.55M$ -5.72M
Other Income/Expenses
$ 51.72M$ 32.97M$ -31.65M$ -36.38M$ -10.44M
Pretax Income
$ 63.66M$ 36.01M$ 47.30M$ -10.54M$ 796.64M
Net Income
$ 52.15M$ -5.22M$ 57.14M$ -2.98M$ 629.30M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ 3.02$ -0.31$ 3.44$ -0.18$ 33.13
Diluted EPS
$ 2.94$ -0.31$ 3.31$ -0.18$ 31.85
Weighted Average Shares Outstanding
17.30M 16.87M 16.63M 16.18M 19.00M
Weighted Average Shares Outstanding (Diluted)
17.76M 16.87M 17.25M 16.18M 19.76M
Currency in USD

Ligand Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis